155 related articles for article (PubMed ID: 1333351)
1. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH
Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351
[TBL] [Abstract][Full Text] [Related]
2. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Gurney H; Grill V; Martin TJ
Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988
[TBL] [Abstract][Full Text] [Related]
4. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
5. Serum ionized calcium, nephrogenous and total urinary cyclic AMP and urinary phosphate in normal subjects.
Thode J; Holmegaard SN; Siggaard-Andersen O
Scand J Clin Lab Invest; 1984 Apr; 44(2):111-8. PubMed ID: 6326252
[TBL] [Abstract][Full Text] [Related]
6. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Gurney H; Kefford R; Stuart-Harris R
Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
[TBL] [Abstract][Full Text] [Related]
7. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Tal A; Graves L
South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenous cyclic adenosine monophosphate levels in normocalcemic cancer patients: its significance.
Abramson EC; Kukreja SC; Lad TE; Shemerdiak WP; York PA
Horm Metab Res; 1984 Apr; 16(4):204-7. PubMed ID: 6327481
[TBL] [Abstract][Full Text] [Related]
10. A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia.
Gallacher SJ; Ralston SH; Fraser WD; Dryburgh FJ; Cowan RA; Logue FC; Boyle IT
Bone Miner; 1991 Dec; 15(3):249-56. PubMed ID: 1773137
[TBL] [Abstract][Full Text] [Related]
11. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
12. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
[TBL] [Abstract][Full Text] [Related]
13. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
[TBL] [Abstract][Full Text] [Related]
14. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
15. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
Body JJ; Dumon JC; Thirion M; Cleeren A
J Bone Miner Res; 1993 Jun; 8(6):701-6. PubMed ID: 8328312
[TBL] [Abstract][Full Text] [Related]
16. Maximal PTH secretory rate and set point for calcium in normal subjects and patients with primary hyperparathyroidism. In vivo studies.
Gardin JP; Patron P; Fouqueray B; Prigent A; Paillard M
Miner Electrolyte Metab; 1988; 14(4):221-8. PubMed ID: 2850460
[TBL] [Abstract][Full Text] [Related]
17. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
Sekine M; Takami H
Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
[TBL] [Abstract][Full Text] [Related]
18. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
Thiebaud D; Jaeger P; Burckhardt P
J Bone Miner Res; 1990 Mar; 5(3):221-6. PubMed ID: 2333780
[TBL] [Abstract][Full Text] [Related]
19. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
20. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
